IFNB1 and breast cancer: To investigate whether this dysregulation interferes with IFN-Is production under chemotherapy, we transfected an in-house established primary BC cell line (SYBC1) with an IFNB1 promoter reporter plasmid, and conducted an unbiased screening by omitting specific individual essential or non-essential amino acids from the cell culture medium and treated cells with cisplatin, which was the backbone of NAC regimens for BC.